By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
MedWorld NewsMedWorld News
  • Food & Diet
  • Health Conditions
  • Heart Health
  • Mental Health
  • Nutrition & Fitness
  • Supplements
  • Beauty
Notification Show More
Font ResizerAa
MedWorld NewsMedWorld News
Font ResizerAa
  • Food & Diet
  • Health Conditions
  • Heart Health
  • Mental Health
  • Nutrition & Fitness
  • Supplements
  • Beauty
  • Food & Diet
  • Health Conditions
  • Heart Health
  • Mental Health
  • Nutrition & Fitness
  • Supplements
  • Beauty
Follow US
© Med World News 2025
Home » Health Conditions » Analysts Share Mixed Views on Elis SA and Rolls-Royce Holdings
Health Conditions

Analysts Share Mixed Views on Elis SA and Rolls-Royce Holdings

Analyst Perspectives on the Industrial Goods Sector

Elis SA Analysis

Recent insights from analysts have focused on Elis SA (ELSSF), particularly from David Cerdan of Kepler Capita

Sophia Lin
Last updated: September 23, 2025 8:42 pm
By Sophia Lin - Innovation & MedTech Reporter

Analyst Perspectives on the Industrial Goods Sector

Elis SA Analysis

Recent insights from analysts have focused on Elis SA (ELSSF), particularly from David Cerdan of Kepler Capital, who maintained a Buy rating in a report dated July 31. Cerdan assigned a price target of EUR 30.00, while the stock closed last Tuesday at $29.00. His recommendations for Elis SA have an impressive average return of 14.4%.

Contents
Analyst Perspectives on the Industrial Goods SectorElis SA AnalysisRolls-Royce Holdings Insights

According to TipRanks.com, Cerdan ranks #9423 out of 9914 analysts. The current consensus among analysts is a Strong Buy, with an average price target of $32.84, suggesting a potential upside of 13.2% from current trading levels. UBS also confirmed a Buy rating on the stock, citing a price target of EUR 27.00.

Rolls-Royce Holdings Insights

Turning to Rolls-Royce Holdings (RYCEF), Kepler Capital’s analyst Aymeric Poulain issued a Hold rating on July 31, setting a price target of p952.00. The stock closed at $14.19 last Friday. Poulain’s recommendations on Rolls-Royce have yielded an average return of 43.7%.

Poulain is ranked #364 out of 9914 analysts on TipRanks.com. The consensus for Rolls-Royce Holdings is a Moderate Buy, with a collective price target of $12.53.

Health Conditions

Share This Article
Facebook Whatsapp Whatsapp LinkedIn Threads Email Copy Link
Ditch the Multivitamins: 5 Nutrient-Dense Foods Doctors Recommend

Doctors suggest whole foods like spinach, lentils, and berries as powerful alternatives…

Trump Admin Launches Medicare Pilot for Weight-Loss Drugs

Trump’s $1.6B pilot could bring weight-loss drugs like Ozempic to Medicare and…

Teachers Balance Side Jobs to Make Ends Meet

Maddie Baker juggles teaching and social media to earn $63K. She budgets…

You Might Also Like

Health Conditions

New Walk With a Doc Program Launches in Chicago Heights

By David Alvarez
Health Conditions

Alarming Increase in Rectal Cancer Rates Among Young Adults

By Dr. Natalie Rhodes
Health Conditions

Walking 78 Minutes Daily Can Combat Back Pain and Heart Disease

By Dr. Natalie Rhodes
Health Conditions

B.C. Enhances HPV Vaccine Access and Updates Immunization Schedule

By Maya Townsend
Facebook X-twitter Instagram Linkedin
Category
  • Beauty
  • Food & Diet
  • Health Conditions
  • Heart Health
  • Mental Health
  • Nutrition & Fitness
  • Supplements
  • About Us
  • Contact
  • Privacy Policy
  • Grow Big Agency Sites:
  • US Reader
  • London Business Journal
  • New York Headlines
  • Celeb Time
  • The Sports Report
  • Techno Reporter
Copyright © 2025, MedWorld News. All Rights Reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?